STOCK TITAN
  1. Home
  2. News
  3. ESPR

Esperion Therapeutics Inc. - ESPR STOCK NEWS

Welcome to our dedicated news page for Esperion Therapeutics (Ticker: ESPR), a resource for investors and traders seeking the latest updates and insights on Esperion Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Esperion Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Esperion Therapeutics's position in the market.

News
Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity
Rhea-AI Summary
Esperion (Nasdaq: ESPR) presented positive results from the CLEAR Outcomes trial at the 2024 American College of Cardiology’s Annual Scientific Sessions. Patients with obesity on NEXLETOL had a 23% lower risk of MACE-4 compared to placebo. The trial highlighted benefits in women and Hispanic/Latinx patients, emphasizing the importance of early LDL-C lowering for reducing cardiovascular events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024
Rhea-AI Summary
Esperion (Nasdaq: ESPR) CEO Sheldon Koenig rings Nasdaq opening bell to celebrate FDA approval of new labels for products, aiming to reduce prescribing limitations and help more patients reach LDL-cholesterol goals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.1%
Tags
none
-
News
Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
Esperion (ESPR) to participate in the 23rd Annual Needham Virtual Healthcare Conference on April 9, 2024. The company aims to improve outcomes for patients with cardiovascular diseases by developing innovative medicines. Esperion focuses on reducing LDL-cholesterol levels to help patients reach their health goals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.05%
Tags
conferences
News
Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24
Rhea-AI Summary
Esperion announces the acceptance of three CLEAR Outcomes subgroup analyses as poster presentations at the 2024 American College of Cardiology’s Annual Scientific Session. The company will present subset analyses in women, Hispanic/Latinx patients, and patients with obesity, showcasing additional data from the pivotal CLEAR Outcomes trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.05%
Tags
none
-
News
U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
Rhea-AI Summary
Esperion (ESPR) receives FDA approval for expanded labels for NEXLETOL and NEXLIZET, broadening treatable population to 70 million in the U.S. The approvals are based on positive CLEAR Outcomes data, allowing for cardiovascular risk reduction and LDL-C lowering in primary and secondary prevention patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.53%
Tags
fda approval
-
News
CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events
Rhea-AI Summary
Daiichi Sankyo and Esperion Therapeutics receive positive CHMP opinions for bempedoic acid and bempedoic acid / ezetimibe FDC, aiming to reduce LDL-C and cardiovascular risk in Europe. The European Commission is expected to make a decision in 1H 2024. The opinions are based on Phase 3 CLEAR Outcomes trial, showing a 13% reduction in major adverse cardiovascular events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.53%
Tags
none
News
Esperion Reports Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Esperion (ESPR) reports strong financial growth in FY23 with U.S. net product revenue up 40% Y/Y to $78.3 million. Q4 U.S. net product revenue grew 39% Y/Y to $20.8 million. The company resolved litigation, receiving $100 million and potential cost savings. Positive interactions with FDA and EMA for cardiovascular indications. Recent equity offering raised $97.8 million. FDA approved updated LDL-C indication for NEXLETOL and NEXLIZET. Financial results show total revenue growth of 54% Y/Y to $116.3 million in FY23. Operating expenses for 2024 expected to be $225-245 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.27%
Tags
earnings
-
News
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Rhea-AI Summary
Esperion (ESPR) granted 66 new employees 204,900 restricted stock units (RSUs) under the 2017 Inducement Equity Incentive Plan. Each RSU will vest over time, subject to continued employment. Esperion focuses on developing medicines for cardiovascular diseases, aiming to improve patient outcomes by lowering LDL-cholesterol levels.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27
Rhea-AI Summary
Esperion (NASDAQ: ESPR) to report Q4 and full year 2023 financial results on February 27, 2024. Webcast to discuss financial results and business updates. Esperion focuses on innovative medicines for cardiovascular and cardiometabolic diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.31%
Tags
conferences earnings
News
RFK, Esperion Therapeutics Announce 2024 Promotional Schedule
Rhea-AI Summary
RFK Racing and Esperion Therapeutics have announced a promotional schedule for the 2024 season, featuring a four-race slate highlighting NEXLIZET and NEXLETOL, used to reduce LDL-cholesterol. The season debut comes in the first race at Richmond this spring, with additional races at North Wilkesboro, Pocono, and Talladega. The partnership between RFK and Esperion will promote a myriad of campaigns and initiatives, including National Wear Red Day, American Heart Month, Stress Awareness Month, Women’s Health Awareness Month, Men’s Health Awareness Month, a Wellness Walk, Cholesterol Education Month, World Heart Day, National Health Education Week, and Family Health History Day. NEXLIZET should not be used in patients who have had a previous allergic reaction to ezetimibe. NEXLIZET and NEXLETOL can increase levels of uric acid in the blood which can lead to gout. Esperion's CEO expressed excitement about the robust marketing campaign and the race schedule, highlighting the combined efforts on promoting cholesterol awareness and various additional health awareness months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.27%
Tags
none
Stock ESPR logo
Esperion Therapeutics Inc.

Nasdaq:ESPR

ESPR Rankings

#3221 Ranked by Market Cap
#5465 Ranked by Stock Gains
N/A Ranked by Dividends

ESPR Stock Data

396.01M
183.65M
0.45%
39.06%
10.77%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Ann Arbor

About ESPR

esperion therapeutics, inc. is a pharmaceutical company focused on developing and commercializing first-in-class, oral, ldl-c lowering therapies for the treatment of patients with hypercholesterolemia. etc-1002, the company's lead product candidate, is an inhibitor of atp citrate lyase, a well-characterized enzyme on the cholesterol biosynthesis pathway; the same pathway that includes hmg-coa reductase, the enzyme target of statins. the company has successfully completed its phase 1 and phase 2 development programs for etc-1002, and plans to initiate its etc-1002 phase 3 development program by the end of 2015. for more information, please visit www.esperion.com.